3-{[1-(Dodecyloxy)-3-methoxypropan-2-YL]oxy}propane-1,2-diol | 93177-59-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 3-{[1-(Dodecyloxy)-3-methoxypropan-2-YL]oxy}propane-1,2-diol
• 英文别名: 3-(1-dodecoxy-3-methoxypropan-2-yl)oxypropane-1,2-diol
• CAS: 93177-59-4
• 化学式: C₁₉H₄₀O₅
• 分子量: 348.5
• InChiKey: XMIRPRQAMNUBDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Percutaneous absorption accelerator and preparation containing same
  申请人：Kao Corporation

  公开号：EP0162239A1

  公开（公告）日：1985-11-27

  The invention relates to a percutaneous absorption accelerator comprising an ether compound of a glycerol or a polyglycerol and an alcohol as an effective component.

  本发明涉及一种经皮吸收促进剂，其有效成分包括甘油或聚甘油与醇的醚化合物。
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTIC NERVE DISORDERS COMPRISING 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP2407454A1

  公开（公告）日：2012-01-18

  Disclosed is a compound useful as a preventive or therapeutic agent for optic nerve disorders, an inhibitor of retinal ganglion cell death or an agent for restoring the expression level of a neurofilament light chain, particularly a compound capable of exhibiting the abovementioned pharmacological activities when administered orally. A 4,6-dichloro-1H-indole-2-carboxylic acid derivative or a salt thereof can significantly inhibit the decrease in the number of cells in a retinal ganglion cell layer of an NMDA-induced rat retinal disorder model when administered to the model orally, and can also restore the decrease in the expression level of a neurofilament light chain in a retina of the model when administered to the model intravitreally (intraocular local administration). Therefore, the compound or a salt thereof is useful as a preventive or therapeutic agent for optic nerve disorders, an inhibitor of retinal ganglion cell death or an agent for restoring the expression level of a neurofilament light chain.

  本发明公开了一种可作为视神经疾病的预防或治疗剂、视网膜神经节细胞死亡抑制剂或恢复神经丝蛋白轻链表达水平的药物的化合物，特别是一种在口服给药时能够表现出上述药理活性的化合物。一种 4,6-二氯-1H-吲哚-2-羧酸衍生物或其盐在口服给药 NMDA 诱导的大鼠视网膜紊乱模型时，能显著抑制该模型视网膜神经节细胞层细胞数量的减少；在玻璃体内给药（眼内局部给药）时，还能恢复该模型视网膜中神经丝轻链表达水平的减少。因此，该化合物或其盐类可用作视神经疾病的预防或治疗药物、视网膜神经节细胞死亡抑制剂或恢复神经丝轻链表达水平的药物。
• Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
  申请人：DFB SORIA, LLC

  公开号：US10555898B2

  公开（公告）日：2020-02-11

  Disclosed are methods useful for the topical therapeutic treatment of skin malignancies including skin cancers and cutaneous metastases using compositions containing nanoparticles of paclitaxel or other taxanes.

  公开了使用含有紫杉醇或其他类固醇纳米颗粒的组合物局部治疗皮肤恶性肿瘤（包括皮肤癌和皮肤转移瘤）的方法。
• Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
  申请人：CRITITECH, INC.

  公开号：US11058639B2

  公开（公告）日：2021-07-13

  Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

  所公开的是通过将局部给药含有抗肿瘤微粒（如紫杉烷微粒）的组合物与全身给药含有免疫治疗剂的组合物相结合来治疗癌症的组合治疗方法。局部给药方法包括局部应用、肺部给药、瘤内注射、腹膜内注射和囊内注射。
• Transdermal carrier
  申请人：Ampersand Biopharmaceuticals, Inc.

  公开号：US11052152B2

  公开（公告）日：2021-07-06

  Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

  本发明公开了用于局部治疗的改进配方，可确保至少通过皮肤、指甲或毛囊局部透皮或全身输送活性剂。